Investors in Capricor Therapeutics urged to act by lawsuit deadline

On September 28, 2026, investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) are urged to take action as the deadline approaches for a securities class action lawsuit. The lawsuit, brought by Faruqi & Faruqi, LLP, alleges that the company and its executives violated federal securities laws by making false and misleading statements about the regulatory prospects of Deramiocel, a therapy for Duchenne muscular dystrophy.

According to the complaint, Capricor allegedly adopted changes to its pre-specified statistical analysis plan without obtaining prior FDA approval, which significantly increased the risk that the FDA would conclude the clinical results did not provide substantial evidence of Deramiocel's effectiveness. This, in turn, posed a substantial risk to the drug's regulatory approval.

The lawsuit details two significant events that affected Capricor's stock price. On July 27, 2026, the FDA released briefing documents stating that the benefit-risk assessment for Deramiocel appeared unfavorable in the absence of evidence of effectiveness. This news caused Capricor's stock to drop 64%, closing at $7.00 per share on an unusually heavy trading day. Two days later, on July 30, 2026, the FDA's advisory committee voted 9-3 against the efficacy of Deramiocel for treating Duchenne muscular dystrophy-associated cardiomyopathy. This vote led to a further 36% decline in the stock, closing at $4.19 per share.

Faruqi & Faruqi, LLP, a leading national securities law firm, is reminding investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, of the deadline to join the lawsuit. The firm encourages anyone with information regarding Capricor's conduct to come forward, including whistleblowers, former employees, and shareholders.

Any investor seeking to participate in the lawsuit has until September 28, 2026, to file a motion to serve as lead plaintiff. A lead plaintiff is appointed by the court to direct the litigation and make key strategic decisions. Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995.